PARIS (Reuters) - French pharmaceuticals group Sanofi-Aventis said on Wednesday that data showed improvements in work performance in patients with chronic insomnia treated with its blockbuster Ambien drug ."Patients with chronic insomnia can have a higher frequency of work-related problems including absenteeism, an increased rate of accidents, difficulty performing duties and less job satisfaction,” Sanofi said in a statement.
